Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05582538
Title Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC Patients (ATRiBRAVE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors IFOM, The FIRC Institute of Molecular Oncology
Age Groups: senior | adult
Covered Countries ITA

No variant requirements are available.